LeMaitre Vascular, Inc. (LMAT) Stock: Price, Forecast & Analyst Target
LeMaitre Vascular, Inc. (LMAT) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $75.58 (-0.68%), as of the Nov 18, 2026 trading session; market cap $1.73B.
Educational signal · not a buy or sell recommendation · How to read this
LeMaitre Vascular, Inc. · LMAT · NASDAQ
LeMaitre Vascular, Inc. specializes in medical devices and implants for peripheral vascular disease. Their diverse product portfolio and direct sales model contribute to a strong market presence.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · LeMaitre Vascular (LMAT)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $68M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 4 of the last 8 reports
- Altman Z 6.80 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $75.58 | |
| Change on the day | -0.68% | |
| 52-week range | $75.58 – $118.01 | |
| Market capitalisation | $1.73B | — |
| Price / earnings (trailing) | 27.28 | |
| Shares traded on the day | 222.7K |
Price & events
Other perspectives
Council score for LeMaitre Vascular (LMAT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is LeMaitre Vascular (LMAT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LeMaitre Vascular, Inc. (LMAT) is listed on NASDAQ. It employs 651 people and is led by George W. LeMaitre. In Q3 FY2026 it reported revenue of $68M and net income of $15M. The market values it at $1.73B.
What do the latest results show for LeMaitre Vascular (LMAT)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $68M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $68M | $15M | $0.65 (diluted) |
| Q2 FY2026 | $70M | $17M | $0.74 (diluted) |
| Q1 FY2026 | $67M | $16M | $0.68 (diluted) |
| Q4 FY2025 | $64M | $16M | $0.68 (diluted) |
What are the financial strengths and risks for LeMaitre Vascular (LMAT)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. The distress and quality screens read Altman Z 6.80 · Piotroski F 6. Trailing ratios: ROE 15.6% · ROA 6.6% · current ratio 14.60.
What should you watch next at LeMaitre Vascular (LMAT)?
Short answer · as of
Current published price targets run low $86.00 · high $110.00 · consensus $97.00 · median $95.00 against a quoted price of $75.58 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does LeMaitre Vascular compare with its peers?
Short answer
LeMaitre Vascular's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $55.45 Nov 18, 2026 | $2.82B | 95 5-pillar Nov 18, 2026 | |
| LeMaitre Vascular (LMAT) — this page | $75.58 | $1.73B | 88 |
| $122.86 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $85.93 Nov 18, 2026 | $5.15B | 81 5-pillar Nov 18, 2026 | |
| $25.35 Nov 18, 2026 | $1.27B | 80 5-pillar Nov 18, 2026 | |
| $15.36 Nov 18, 2026 | $4.20B | 73 5-pillar Nov 18, 2026 | |
| $178.48 Nov 18, 2026 | $4.46B | 73 5-pillar Nov 18, 2026 | |
| $48.69 Nov 18, 2026 | $2.03B | 64 5-pillar Nov 18, 2026 | |
| $28.22 Nov 18, 2026 | $3.51B | 62 5-pillar Nov 18, 2026 | |
| $3.36 Nov 18, 2026 | $535M | 41 5-pillar Nov 18, 2026 | |
| $11.32 Nov 18, 2026 | $476M | 37 5-pillar Nov 18, 2026 | |
| $8.52 Nov 18, 2026 | $1.70B | 31 5-pillar Nov 18, 2026 | |
| $45.83 Nov 18, 2026 | $3.37B | 27 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $86.00 – $110.00
- Consensus target
- $97.00
- Median target
- $95.00
Consensus record · Captured .
Measured against a quoted price of $75.58 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 3, 2026
- Transactions
- 108
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 0
- Other transactions
- 108
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LMAT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LMAT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about LeMaitre Vascular (LMAT)?
Investor Questions: LMAT Stock
These answers are editorial: 1 of these 9 answers is drawn from the LMAT research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LMAT?
LMAT carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. LeMaitre Vascular, Inc. specializes in medical devices and implants for peripheral vascular disease.
Is LMAT a good stock to buy?
Stock Expert AI does not rate LMAT buy, sell or hold. LeMaitre Vascular, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LMAT stock price today?
The last price recorded for LeMaitre Vascular, Inc. (LMAT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LMAT price target?
The analyst consensus price target for LeMaitre Vascular, Inc. (LMAT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does LeMaitre Vascular, Inc. do?
LeMaitre Vascular, Inc. specializes in the design, marketing, and sale of medical devices and implants used in the treatment of peripheral vascular disease.
What are the key factors to evaluate for LMAT?
LeMaitre Vascular, Inc. (LMAT) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does LMAT data refresh on this page?
LMAT's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LMAT's recent stock price performance?
LeMaitre Vascular, Inc. (LMAT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in vascular surgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LMAT overvalued or undervalued right now?
The trailing P/E of LeMaitre Vascular, Inc. (LMAT) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com